Lv7
3290 积分 2021-12-14 加入
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
7天前
已完结
Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial
2个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
2个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
2个月前
已完结
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
2个月前
已完结
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial
3个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
3个月前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
4个月前
已完结
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
5个月前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
